(Total Views: 771)
Posted On: 06/01/2024 11:35:05 PM
Post# of 154137
Quote:
You can’t read this article and not walk away without the impression the medical community is throwing darts at it, typically with multiple agent regimens.
Quote:
One of the main obstacles in achieving efficacy with ICIs is the limited infiltration of immune cells in the TME. In the case of MSS CRC, there is a lack of sufficient immune cells available for activation by ICIs in the TME.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770832/
Leronlimab boosts CD8+ T cells (immune cells) while stripping away the tumors defenses that keep those immune cells away.
As a side note a nice commentary on CCR5/CCL5 and CRC -
https://jitc.bmj.com/content/12/5/e008722
(16)
(0)
